Pharmaceutical Raw Materials
Veterinary API
Antiallergic Drugs
Hormones and Endocrine Drugs
Drug Metabolism
Pharmaceutical Intermediates
Synthetic Anti Infective Drugs
Specialty Drugs
Vitamins and Minerals Medicines
Feed Drug Additive
Antineoplastic Agents
Nervous System Drugs
Respiratory Drugs
Diagnostic Agents
Anti Stress Drugs
Antipyretic Analgesics
Antiparasitic Drugs
Circulatory System Drugs
Biochemicals
Blood System Drugs
Immune System Medication
Pharmaceutical Excipients
Fluid, Electrolyte, and Acid-Base Balance
Urinary System Drugs
Antibiotics
Anesthetic Agents
Inhibitors
Other Chemical Drugs
Digestive System Drugs
Alias
More Information
Tovok; BIBW2992; (S)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-((Tetrahydrofuran-3-Yl)Oxy)Quinazolin-6-Yl)-4-(Dimethylamino)But-2-Enamide; 2-Butenamide, N-[4-[(3-Chloro-4-Fluorophenyl)Amino]-7-[[(3S)-Tetrahydro-3-Furanyl]Oxy]-6-Quinazolinyl]-4-(Dimethylamino)-; (E/Z)-Afatinib; Afatinib Cis-Trans Isomer; Bibw-2292
Brief Introduction
Afatinib is an aminocrotonyl amino substituted quinazoline derivative used to treat cancers and diseases of respiratory tract, lung, gastrointestinal tract, bile duct and gallbladder.
Suppliers
View More Vendors (2） >
Alias
More Information
1-(4-Methoxyphenyl)-7-Oxo-6-[4-(2-Oxopiperidin-1-Yl)Phenyl]-4,5-Dihydropyrazolo[3,4-C]Pyridine-3-Carboxamide; Eliquis; Unii-3Z9Y7Uwc1J; Bms-562247-01; Bms-562247
Brief Introduction
Apixaban (inn, trade name eliquis) is an anticoagulant used to prevent venous thromboembolism and atrial fibrillation stroke. It is a direct factor Xa inhibitor. Apixaban has been listed in Europe since May 2011. The drug was developed by a joint venture between Pfizer and Bristol Myers Squibb.
Suppliers
View More Vendors (2） >
CAS:571190-30-2
Molecular Formula:C24H29N7O2
Alias
More Information
Ibrance(Trade name); Pabcilib; Pabosi Ni
Brief Introduction
Pabcicilib is an inhibitor of cyclin dependent kinase (CDK) 4 and 6. Cyclin D1 and CDK4 / 6 are downstream signaling pathways leading to cell proliferation. In vitro, the proliferation of ER positive breast cancer cells was inhibited by blocking the progression from G1 to S phase. Compared with the treatment of each drug alone, the combination of pabacib and anti estrogen resulted in decreased phosphorylation of retinoblastoma protein (RB), decreased E2F expression and signal, and prevented growth. In vitro treatment of ER positive breast cancer cell lines with combination of pabacib and anti estrogen resulted in increased cell senescence, which lasted up to 6 days after drug removal.
Suppliers
View More Vendors (2） >
CAS:857890-39-2
Molecular Formula:C22H23ClN4O7S
Alias
More Information
4-(3-Chloro-4-(Cyclopropylaminocarbonyl)Aminophenoxy)-7-Methoxy-6-Quinolinecarboxamide Methanesulfonate; E7080 Mesylate; UNII-3J78384F61; Lenvatinib Mesilate (JAN)
Brief Introduction
Lovatinib mesylate is the mesylate of lovatinib. Lovatinib is a multi-target tyrosine kinase inhibitor developed by Japan Weicai company. It has a novel binding mode. In addition to inhibiting other tyrosine kinases related to angiogenesis and carcinogenic signal pathways involved in tumor proliferation, It can also selectively inhibit the kinase activity of vascular endothelial growth factor (VEGF) receptor, such as VEGF-1, VEGF-2 and vegf-3.
Suppliers
View More Vendors (2） >
CAS:1231929-97-7
Molecular Formula:C27H32F2N8
Alias
More Information
N-(5-((4-Ethylpiperazin-1-yl)Methyl)Pyridin-2-yl)-5-Fluoro-4-(4-Fluoro-1-Isopropyl-2-Methyl-1H-Benzo[d]Imidazol-6-yl)Pyrimidin-2-Amine
Brief Introduction
Abemaciclib is an oral cyclin dependent kinase CDK4 / 6 inhibitor
Suppliers
View More Vendors (2） >
Tablets；50mg/100mg/150mg/200mg，class 4 drug
/
Pharm Grade
Inquiry (
10
/ 10
)
Clear All
Sign In
Error!